Last updated on November 2019

CTH-301: An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Brief description of study

A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.


Clinical Study Identifier: TX216175

Find a site near you

Start Over

EvergreenHealth Research Program

12039 NE 128th Street, Suite 300 Kirkland, WA USA
  Connect »